# Vanderbilt-Ingram Cancer Center

Source: https://onco.cc/institutions/vanderbilt-ingram/  
OnCo record `vanderbilt-ingram` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tennessee's NCI comprehensive centre, birthplace of the My Cancer Genome knowledge base and the molecular subtypes of triple-negative breast cancer.

## Summary

NCI-designated in 1995 and comprehensive since 2001, Vanderbilt-Ingram serves Tennessee and the mid-South. William Pao, who had discovered the EGFR T790M resistance mutation, launched My Cancer Genome here in 2011, one of the first public precision-oncology knowledge bases. Brian Lehmann and Jennifer Pietenpol defined the molecular subtypes of triple-negative breast cancer, Justin Balko studies immunotherapy in TNBC, and Douglas Johnson's work on immune-related adverse events shaped their management. The Southern Community Cohort Study, run from Vanderbilt, is a major resource on cancer disparities in the South. Kimryn Rathmell moved from chairing medicine here to directing the NCI in 2023.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: VICC
- City: Nashville, TN, US
- Type: cancer-center
- NCI designation: comprehensive
- Website: https://www.vicc.org

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Vanderbilt-Ingram_Cancer_Center
- Vanderbilt-Ingram Cancer Center: https://www.vicc.org
- Clinical trials: https://www.vicc.org/clinical-trials
- My Cancer Genome: https://www.mycancergenome.org

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [PIK3CA / PI3K-alpha](https://onco.cc/targets/pik3ca/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)
- terms: [Immune-related adverse events (irAEs)](https://onco.cc/terms/irae/)
- people: [Brian I. Rini](https://onco.cc/people/brian-rini/), [Martha Rivers Ingram](https://onco.cc/people/martha-ingram/)
- bottlenecks: [Trials do not represent the people who get cancer](https://onco.cc/bottlenecks/b-trial-diversity/)
- key papers: [Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies](https://onco.cc/key-papers/paper-lehmann-tnbc-subtypes-jci-2011/), [Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes](https://onco.cc/key-papers/paper-lehmann-tnbc-subtype-multiomics-nat-commun-2021/), [Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection](https://onco.cc/key-papers/paper-lehmann-tnbctype-4-refinement-plos-one-2016/), [Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs](https://onco.cc/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/)

---
JSON: https://onco.cc/api/v1/entities/vanderbilt-ingram.json